MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial

Hong-Hu Zhu,Xiao-Hui Zhang,Ya-Zhen Qin,Dai-Hong Liu,Hao Jiang,Huan Chen,Qian Jiang,Lan-Ping Xu,Jin Lu,Wei Han,Li Bao,Yu Wang,Yu-Hong Chen,Jing-Zhi Wang,Feng-Rong Wang,Yue-Yun Lai,Jun-Yue Chai,Li-Ru Wang,Liu Yr,Kai-Yan Liu,Bin Jiang,Xiao-Jun Huang

MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial

2013

We aimed to improve the outcome of t(8;21) acute myeloid leukemia (AML) in the first complete remission (CR1) by applying risk-directed therapy based on minimal residual disease (MRD) determined by RUNX1/RUNX1T1 transcript levels. Risk-directed therapy included recommending allogeneic hematopoietic

Keywords:

Minimal residual disease
Immunology
RUNX1T1
RUNX1
Myeloid leukemia
Multicenter trial
Haematopoiesis
Medicine
complete remission
risk stratification

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

193

Citations